Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and ...
May 20, 2021
0
2